Lipid-lowering drugs are expected to assist in the treatment of leukemia

Share This Post

The latest research found that some statins can improve the efficacy of chemotherapy drugs used to treat blood cancer in mouse models. Statins are drugs that treat patients with reduced fat in the blood. They are commonly used to lower triglyceride and cholesterol levels and reduce fat associated with heart attacks and strokes. In this new experiment, the researchers found that they may also be used to treat certain blood cancers.

Previous research has shown that statins promote apoptosis (natural cell death) in certain types of cancer, and this finding suggests that they may be useful in treating these cancers. In this study, the researchers found that simvastatin enhanced the efficacy of Venetoclax against chronic lymphocytic leukemia in a mouse model. It helps to reduce lymphoma by increasing the apoptosis signal in cancer cells, resulting in increased survival time. They also pointed out that this finding is more effective than any drug given alone.

The researchers were encouraged by the results of this study and began three clinical trials involving the testing of Venetoclax for the treatment of chronic lymphocytic leukemia, looking for data on patients who had received statins. They found that these patients responded better to cancer by 2.7 times than those who did not take statins.

Researchers say that if statins have the same effect in humans, millions of people around the world often use them to lower cholesterol levels. In addition to reducing fat in the blood, they have also been shown to have no side effects. The researchers believe that clinical trials should be conducted to determine whether statins can improve the prognosis of patients with leukemia and other blood cancers.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy